Shares of Anglo-Swedish pharma giant AstraZeneca (AZN) are down over 11 percent year-to-date as the company gears up to face another patent cliff this year. This pales before the 4 percent gain by its predator Pfizer and Merck's 8 percent advance.
from RTT - Biotech http://ift.tt/1WKsWtW
via IFTTT
No comments:
Post a Comment